Claudia Aura

5.3k total citations · 1 hit paper
35 papers, 2.1k citations indexed

About

Claudia Aura is a scholar working on Oncology, Molecular Biology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Claudia Aura has authored 35 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 13 papers in Molecular Biology and 13 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Claudia Aura's work include HER2/EGFR in Cancer Research (13 papers), Monoclonal and Polyclonal Antibodies Research (10 papers) and PI3K/AKT/mTOR signaling in cancer (5 papers). Claudia Aura is often cited by papers focused on HER2/EGFR in Cancer Research (13 papers), Monoclonal and Polyclonal Antibodies Research (10 papers) and PI3K/AKT/mTOR signaling in cancer (5 papers). Claudia Aura collaborates with scholars based in Spain, United States and Belgium. Claudia Aura's co-authors include Paolo Nucíforo, José Jiménez, José Baselga, Vicente Peg, José Baselga, Maurizio Scaltriti, Holger Eidtmann, Joan Seoane, Catherine Ellis and Evandro de Azambuja and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature Medicine and Journal of Clinical Oncology.

In The Last Decade

Claudia Aura

34 papers receiving 2.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab

2015 432 citations Roberto Salgado, Carsten Denkert et al. JAMA Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Claudia Aura Spain	17	1.3k	868	618	428	341	35	2.1k
Patricia Galván Spain	20	1.4k 1.1×	947 1.1×	997 1.6×	671 1.6×	263 0.8×	69	2.4k
Jane Kendrew United Kingdom	22	1.1k 0.9×	1.5k 1.8×	561 0.9×	638 1.5×	313 0.9×	33	2.7k
Teresa C. Dugger United States	16	1.7k 1.4×	1.7k 1.9×	503 0.8×	393 0.9×	388 1.1×	22	2.7k
Cristiano Ferrario Canada	18	1.3k 1.0×	476 0.5×	653 1.1×	515 1.2×	208 0.6×	81	1.9k
Min Hye Jang South Korea	20	1.0k 0.8×	610 0.7×	473 0.8×	279 0.7×	219 0.6×	42	1.7k
Oleg Gluz Germany	23	1.5k 1.2×	625 0.7×	1.1k 1.8×	521 1.2×	301 0.9×	142	2.4k
Ulrike Nitz Germany	22	1.5k 1.2×	561 0.6×	1.1k 1.8×	469 1.1×	331 1.0×	135	2.4k
Laia Paré Spain	25	1.5k 1.2×	848 1.0×	936 1.5×	716 1.7×	232 0.7×	98	2.5k
Florence Lerebours France	29	1.4k 1.1×	915 1.1×	1.2k 2.0×	692 1.6×	322 0.9×	97	2.6k
Frances Daley United Kingdom	27	759 0.6×	886 1.0×	934 1.5×	539 1.3×	528 1.5×	52	2.3k

Countries citing papers authored by Claudia Aura

Since Specialization

Citations

This map shows the geographic impact of Claudia Aura's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Claudia Aura with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Claudia Aura more than expected).

Fields of papers citing papers by Claudia Aura

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Claudia Aura. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Claudia Aura. The network helps show where Claudia Aura may publish in the future.

Co-authorship network of co-authors of Claudia Aura

This figure shows the co-authorship network connecting the top 25 collaborators of Claudia Aura. A scholar is included among the top collaborators of Claudia Aura based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Claudia Aura. Claudia Aura is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Mazo, Claudia, Claudia Aura, Arman Rahman, William M. Gallagher, & Catherine Mooney. (2022). Application of Artificial Intelligence Techniques to Predict Risk of Recurrence of Breast Cancer: A Systematic Review. Journal of Personalized Medicine. 12(9). 1496–1496. 19 indexed citations

Rahman, Arman, et al.. (2020). Advances in tissue-based imaging: impact on oncology research and clinical practice. Expert Review of Molecular Diagnostics. 20(10). 1027–1037. 10 indexed citations

Guttà, Cristiano, Arman Rahman, Claudia Aura, et al.. (2020). Low expression of pro-apoptotic proteins Bax, Bak and Smac indicates prolonged progression-free survival in chemotherapy-treated metastatic melanoma. Cell Death and Disease. 11(2). 124–124. 26 indexed citations

Watson, R. William G., Claudia Aura, Janet McCormack, et al.. (2020). Inhibition of Serum Response Factor Improves Response to Enzalutamide in Prostate Cancer. Cancers. 12(12). 3540–3540. 5 indexed citations

Smedt, Jonathan De, Sofie Van Kelst, Veerle Boecxstaens, et al.. (2017). Vitamin D supplementation in cutaneous malignant melanoma outcome (ViDMe): a randomized controlled trial. BMC Cancer. 17(1). 562–562. 30 indexed citations

Nucíforo, Paolo, Claudia Aura, Eileen Holmes, et al.. (2015). Benefit to neoadjuvant anti-human epidermal growth factor receptor 2 (HER2)-targeted therapies in HER2-positive primary breast cancer is independent of phosphatase and tensin homolog deleted from chromosome 10 (PTEN) status. Annals of Oncology. 26(7). 1494–1500. 27 indexed citations

Vicario, Rocío, Vicente Peg, Beatriz Morancho, et al.. (2015). Patterns of HER2 Gene Amplification and Response to Anti-HER2 Therapies. PLoS ONE. 10(6). e0129876–e0129876. 41 indexed citations

Nucíforo, Paolo, Sheeno Thyparambil, Claudia Aura, et al.. (2015). High HER2 protein levels correlate with increased survival in breast cancer patients treated with anti‐HER2 therapy. Molecular Oncology. 10(1). 138–147. 68 indexed citations

Nucíforo, Paolo, Sheeno Thyparambil, Claudia Aura, et al.. (2015). Abstract P4-11-29: Quantitative measurement of HER2 levels by multiplexed mass spectrometry from FFPE tissue predicts survival in patients treated with anti-HER2 based therapy. Cancer Research. 75(9_Supplement). P4–11.

10.

Salgado, Roberto, Carsten Denkert, Christine Campbell, et al.. (2015). Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab. JAMA Oncology. 1(4). 448–448. 432 indexed citations breakdown →

11.

Mattos‐Arruda, Leticia De, Britta Weigelt, Javier Cortés, et al.. (2014). Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle. Annals of Oncology. 25(9). 1729–1735. 284 indexed citations

12.

García-García, Celina, Yasir H. Ibrahim, Violeta Serra, et al.. (2012). Dual mTORC1/2 and HER2 Blockade Results in Antitumor Activity in Preclinical Models of Breast Cancer Resistant to Anti-HER2 Therapy. Clinical Cancer Research. 18(9). 2603–2612. 118 indexed citations

13.

Llombart‐Cussac, Antonio, Aňa Lluch, Cristian Villanueva, et al.. (2012). SOLTI NeoPARP: A phase II, randomized study of two schedules of iniparib plus paclitaxel and paclitaxel alone as neoadjuvant therapy in patients with triple-negative breast cancer (TNBC).. Journal of Clinical Oncology. 30(15_suppl). 1011–1011. 7 indexed citations

14.

Eichhorn, Pieter J.A., Laura Rodón, Alba Gonzàlez-Juncà, et al.. (2012). USP15 stabilizes TGF-β receptor I and promotes oncogenesis through the activation of TGF-β signaling in glioblastoma. Nature Medicine. 18(3). 429–435. 332 indexed citations

15.

Oliveira, Mafalda, Alejandro Navarro, Leticia De Mattos‐Arruda, et al.. (2012). PI3K pathway (PI3Kp) dysregulation and response to pan-PI3K/AKT/mTOR/dual PI3K-mTOR inhibitors (PI3Kpi) in metastatic breast cancer (MBC) patients (pts).. Journal of Clinical Oncology. 30(15_suppl). 509–509. 8 indexed citations

16.

Scaltriti, Maurizio, Pieter J.A. Eichhorn, Javier Cortés, et al.. (2011). Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2 ⁺ breast cancer patients. Proceedings of the National Academy of Sciences. 108(9). 3761–3766. 251 indexed citations

17.

Scaltriti, Maurizio, Violeta Serra, Emmanuel Normant, et al.. (2011). Antitumor Activity of the Hsp90 Inhibitor IPI-504 in HER2-Positive Trastuzumab-Resistant Breast Cancer. Molecular Cancer Therapeutics. 10(5). 817–824. 44 indexed citations

18.

Scaltriti, Maurizio, Sarat Chandarlapaty, Ludmila Prudkin, et al.. (2010). Clinical Benefit of Lapatinib-Based Therapy in Patients with Human Epidermal Growth Factor Receptor 2–Positive Breast Tumors Coexpressing the Truncated p95HER2 Receptor. Clinical Cancer Research. 16(9). 2688–2695. 114 indexed citations

19.

Andrinolo, Darı́o, Paulo Pereira, Leda Giannuzzi, et al.. (2007). Occurrence of Microcystis aeruginosa and microcystins in Río de la Plata river (Argentina). SHILAP Revista de lepidopterología. 15(1). 8–14. 16 indexed citations

20.

Andrinolo, Darı́o, Daniela Sedán, Claudia Aura, et al.. (2007). Hepatic recovery after damage produced by sub-chronic intoxication with the cyanotoxin microcystin LR. Toxicon. 51(3). 457–467. 35 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact